Epigenetic therapy inhibits metastases by disrupting premetastatic niches

Journal: Nature

Published: 2020-02-26

DOI: 10.1038/s41586-020-2054-x

Affiliations: 18

Authors: 48

Go to article
Institutions Share
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States of America (USA) 0.42
Department of Surgery, JHU, United States of America (USA) 0.17
MOE Key Laboratory of Carcinogenesis and Translational Research at Beijing Cancer Hospital, PKU, China 0.13
W. Harry Feinstone Department of Molecular Microbiology and Immunology, JHU, United States of America (USA) 0.04
Department of Radiation Oncology and Molecular Radiation Sciences, JHU, United States of America (USA) 0.03
Bloomberg-Kimmel Institute for Cancer Immunotherapy, JHU, United States of America (USA) 0.03
NIH NCI Laboratory of Cancer Biology and Genetics (LCBG), United States of America (USA) 0.02
Anne Arundel Medical Center (AAMC), United States of America (USA) 0.02
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA) 0.02
Division of Hematology and Oncology, MUSC, United States of America (USA) 0.02
Vanderbilt University Medical Center (VUMC), United States of America (USA) 0.02
The People's Liberation Army General Hospital (PLAGH), China 0.01
Department of Surgery, UIC, United States of America (USA) 0.01
Juravinski Cancer Centre (JCC), HHS, Canada 0.01
School of Biomedical Engineering, DUT, China 0.01
Department of Oncology, McMaster University, Canada 0.01
Department of Digestive Diseases at Xijing Hospital, FMMU, China 0.01
State Key Laboratory of Cancer Biology (CBSKL), FMMU, China 0.01

Return

Except where otherwise noted © 2020 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER